Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin
- 174 Downloads
Metformin reduces total cholesterol level, low density lipoprotein cholesterol (LDL-C) level, blood glucose level and increases high density lipoprotein cholesterol (HDL-C) level associated with cardiovascular disease. We evaluated effect of metformin on lipid profile in Korean patients with type 2 diabetes aged 64 yeras or older. We retrospectively examined 307 outpatients treated with metformin in a hospital setting with a follow-up period of 4.7 years. Metformin was not associated with the improvement in total cholesterol level (adjusted mean difference; 30.6 mg/dl, 95% CI: 24.9 to 36.4) and HDL-C level (adjusted mean difference; 2.6 mg/dl, 95% CI: 0.09 to 4.64) but may be associated with improvement in triglyceride level (adjusted mean difference; 41.5 mg/dl, 95% CI: 24.7 to 58.3). In comparison to the placebo groups (Kooy et al., 2009), there was a 1.5-fold decrease in triglyceride level and a 2-fold decrease in HDL-C level in our study. The frequency of Scr level that increased above the defined level [Scr ≥ 1.5 mg/dl for male, ≥1.4 mg/dl for female] was 6.7% [mean difference of elevated Scr: −0.9 mg/dl, 95% CI: −0.41 to −1.44, p < 0.002]. To confirm the efficacy of metformin use on triglyceride level and HDL-C level associated with the risk of cardiovascular disease in patient with diabetes, further placebo-controlled investigations are required.
Key wordsCardiovascular disease High density lipoprotein cholesterol Triglyceride
Unable to display preview. Download preview PDF.
- Bristol-myers squibb company: Glucophage and Glucophage XR prescribing information.available: http://packageinserts.bms.com/pi/pi_glucophage.pdf.accessed July 03 (2009).
- Corti, M. C., Guralnik, J. M., Salive, M. E., Harris, T., Field, T. S., Wallace, R. B., Berkman, L. F., Seeman, T. E., Glynn, R. J., Hennekens, C. H., and Havik, R. J., High density lipoprotein cholesterol predicts coronary heart disease mortality in older persons. JAMA, 274, 539–544 (1995).PubMedCrossRefGoogle Scholar
- Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Hessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stvensen, L. W., and Yancy, C. W., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the ACC/AHA task force on practice guideline (trunk), Betheseda (MD). American College of Cardiology foundation (ACCF), August 82p, [694 references] (2005).Google Scholar
- National kidney foundation (K/DOQI)., K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis., 45, S1–S153 [736 references] (2005).Google Scholar
- Ryden, L., Standl, E., Bartnik, M., Betterridge, J., Van den Berghe, G., de Boer, M. J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., and Thrainsdottir, I., Task force on diabetes cardiovascular diseases guideline on diabetes, pre-diabetes, and cardiovascular disease. Eur. Societ. of Cardiology (ESC), 72p [711 references] (2007).Google Scholar
- Sone, H., Mizuno, S., Fujii, H., Yoshimura, Y., Yamasaki, Y., Ishibashi, S., Katayama, S., Saito, Y., Ito, H., Ohashi, Y., Akanuma, Y., and Yamada, N., Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Diabetes Care, 28, 1463–1471 (2005).PubMedCrossRefGoogle Scholar
- Warnick, G. R. and Wood, P. D., National cholesterol education program recommendations for measurement of high-density lipoprotein-cholesterol: executive summary. The national cholesterol education program working group on lipoprotein measurement. Clin. Chem., 41, 1427–1433 (1995).PubMedGoogle Scholar